We attempted treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU), a novel nitrosourea derivative, in a 55-year-old man with advanced-stage primary myelofibrosis. MCNU was given intravenously at a dose of 50 mg once a month. Following MCNU treatment, his anemia and splenomegaly improved markedly. An increased dose of MCNU (100 mg, once a month) was even more effective for relieving the symptoms. Severe side effects resulting from this therapy, such as leukocytopenia or thrombocytopenia, were never observed. These observations indicate that MCNU treatment may be a beneficial management of advanced-stage primary myelofibrosis.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000204866DOI Listing

Publication Analysis

Top Keywords

primary myelofibrosis
12
treatment methyl
8
methyl 6-[3-2-chloroethyl-3-nitrosoureido]-6-deoxy-alpha-d-glucopyranoside
8
advanced-stage primary
8
mcnu treatment
8
mcnu
5
beneficial treatment
4
6-[3-2-chloroethyl-3-nitrosoureido]-6-deoxy-alpha-d-glucopyranoside patient
4
patient primary
4
myelofibrosis attempted
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!